Skip Navigation

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Inhibitor Mechanisms in Cancer and their Therapeutic Manipulation

Loading video...

502 Views

Air date: Wednesday, January 9, 2019, 4:15:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 502
Category: Immunology
Runtime: 01:01:40
Description: Immunology Interest Group (IIG) Seminar Series

Lymphocyte activation gene-3 (LAG3) (CD223) is the third inhibitory receptor (IR) to be targeted in the clinic, consequently garnering considerable interest and scrutiny. LAG3 upregulation is required to control overt activation and prevent the onset of autoimmunity. However, persistent antigen exposure in the tumor microenvironment results in sustained LAG3 expression, contributing to a state of exhaustion manifest in impaired proliferation and cytokine production. The exact signaling mechanisms downstream of LAG3 and interplay with other IRs remain largely unknown. Regulatory T cells (Tregs) inhibit beneficial anti-tumor responses. Treg depletion enhances tumor rejection in animal models and the clinic but also leads to substantial adverse events. Thus approaches have been sought to target Tregs in tumors while limiting systemic autoimmune and inflammatory manifestations. These inhibitory components and they impact in cancer will be the focus of this talk.
Author: Dario A.A. Vignali, PhD, University of Pittsburgh School of Medicine
 
CIT Live ID: 29165
Permanent link: https://videocast.nih.gov/watch=29165